Top

Published in:

01-05-2009 | Preclinical Study

The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance

Authors: Matthew J. Sikora, Kevin E. Cordero, Jose M. Larios, Michael D. Johnson, Marc E. Lippman, James M. Rae

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level of detection; however, androgen concentrations remain unchanged. We were interested in studying the effects of androgens on breast cancer cell proliferation under profound estrogen-deprived conditions. Using in vitro models of estrogen-dependent breast cancer cell growth we show that the androgens testosterone and 5α-dihydrotestosterone induce the growth of MCF-7, T47D and BT-474 cells in the absence of estrogen. Furthermore, we demonstrate that under profound estrogen-deprived conditions these breast cancer cells up-regulate steroidogenic enzymes that can metabolize androgens to estrogens. Lastly, we found that the downstream metabolite of 5α-dihydrotestosterone, 5α-androstane-3β,17β-diol (3βAdiol), is estrogenic in breast cancer cells, and induces growth and ER-signaling via activation of ERα. In conclusion, our results show that breast cancer cells deprived of estrogen up-regulate steroidogenic enzymes and metabolize androgens to estrogen-like steroids. The generation of estrogen-like steroids represents a potential mechanism of resistance to aromatase inhibitors.

Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A (2006) Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66(15):7775–7782. doi:10.1158/0008-5472.CAN-05-3984 PubMedCrossRef

Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M (1993) Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 53(2):266–270PubMed

Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D et al (2007) Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72(8):666–671. doi:10.1016/j.steroids.2007.05.003 PubMedCrossRef

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619–629. doi:10.1200/JCO.2005.09.121 PubMedCrossRef

Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M (1993) Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 77(2):324–331. doi:10.1210/jc.77.2.324 PubMedCrossRef

Lipton A, Demers LM, Harvey HA, Kambic KB, Grossberg H, Brady C et al (1995) Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75(8):2132–2138. doi :10.1002/1097-0142(19950415)75:8≤2132::AID-CNCR2820750816≥3.0.CO;2-UPubMedCrossRef

Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ et al (1995) Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52(5):459–467. doi:10.1016/0960-0760(95)00005-K PubMedCrossRef

Lippman M, Bolan G, Huff K (1976) The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36(12):4610–4618PubMed

Sonne-Hansen K, Lykkesfeldt AE (2005) Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J Steroid Biochem Mol Biol 93(1):25–34. doi:10.1016/j.jsbmb.2004.11.005 PubMedCrossRef

10.

Burak WE Jr, Quinn AL, Farrar WB, Brueggemeier RW (1997) Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase. Breast Cancer Res Treat 44(1):57–64. doi:10.1023/A:1005782311558 PubMed

11.

Maggiolini M, Donze O, Jeannin E, Ando S, Picard D (1999) Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res 59(19):4864–4869PubMed

12.

Lippman ME, Bolan G, Huff K (1975) Human breast cancer responsive to androgen in long term tissue culture. Nature 258(5533):339–341. doi:10.1038/258339a0 PubMedCrossRef

13.

Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S et al (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138(3):863–870. doi:10.1210/en.138.3.863 PubMedCrossRef

14.

Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME (2005) GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92(2):141–149. doi:10.1007/s10549-005-1483-4 PubMedCrossRef

15.

Rae JM, Lippman ME (2004) Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res Treat 83(2):99–107. doi:10.1023/B:BREA.0000010702.10130.29 PubMedCrossRef

16.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262 PubMedCrossRef

17.

Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85(2):151–159. doi:10.1023/B:BREA.0000025406.31193.e8 PubMedCrossRef

18.

Pettersson H, Holmberg L, Axelson M, Norlin M (2008) CYP7B1-mediated metabolism of dehydroepiandrosterone and 5alpha-androstane-3beta, 17beta-diol – potential role(s) for estrogen signaling. FEBS J 275(8):1778–1789. doi:10.1111/j.1742-4658.2008.06336.x PubMedCrossRef

19.

Pak TR, Chung WC, Lund TD, Hinds LR, Clay CM, Handa RJ (2005) The androgen metabolite, 5alpha-androstane-3beta, 17beta-diol, is a potent modulator of estrogen receptor-beta1-mediated gene transcription in neuronal cells. Endocrinology 146(1):147–155. doi:10.1210/en.2004-0871 PubMedCrossRef

20.

Oliveira AG, Coelho PH, Guedes FD, Mahecha GA, Hess RA, Oliveira CA (2007) 5alpha-Androstane-3beta, 17beta-diol (3beta-diol), an estrogenic metabolite of 5alpha-dihydrotestosterone, is a potent modulator of estrogen receptor ERbeta expression in the ventral prostrate of adult rats. Steroids 72(14):914–922. doi:10.1016/j.steroids.2007.08.001 PubMedCrossRef

21.

Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A et al (2005) The androgen derivative 5alpha-androstane-3beta, 17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res 65(12):5445–5453. doi:10.1158/0008-5472.CAN-04-1941 PubMedCrossRef

22.

Weihua Z, Lathe R, Warner M, Gustafsson JA (2002) An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 99(21):13589–13594. doi:10.1073/pnas.162477299 PubMedCrossRef

23.

Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI et al (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98(11):6330–6335. doi:10.1073/pnas.111150898 PubMedCrossRef

24.

Sundin M, Warner M, Haaparanta T, Gustafsson JA (1987) Isolation and catalytic activity of cytochrome P-450 from ventral prostate of control rats. J Biol Chem 262(25):12293–12297PubMed

25.

Isaacs JT, McDermott IR, Coffey DS (1979) Characterization of two new enzymatic activities of the rat ventral prostate: 5 alpha-androstane-3 beta, 17 beta-diol 6 alpha-hydroxylase and 5 alpha-androstane-3 beta, 17 beta-diol 7 alpha-hydroxylase. Steroids 33(6):675–692. doi:10.1016/0039-128X(79)90116-8 PubMedCrossRef

26.

Olsson M, Gustafsson O, Skogastierna C, Tolf A, Rietz BD, Morfin R et al (2007) Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma. Prostate 67(13):1439–1446. doi:10.1002/pros.20630 PubMedCrossRef

27.

Ishikawa T, Glidewell-Kenney C, Jameson JL (2006) Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5 alpha-reductase inhibitor. J Steroid Biochem Mol Biol 98(2–3):133–138. doi:10.1016/j.jsbmb.2005.09.004 PubMedCrossRef

28.

Omoto Y, Lathe R, Warner M, Gustafsson JA (2005) Early onset of puberty and early ovarian failure in CYP7B1 knockout mice. Proc Natl Acad Sci USA 102(8):2814–2819. doi:10.1073/pnas.0500198102 PubMedCrossRef

29.

Martel C, Melner MH, Gagne D, Simard J, Labrie F (1994) Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 104(1):103–111. doi:10.1016/0303-7207(94)90056-6 PubMedCrossRef

30.

Voigt KD, Bartsch W (1986) Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem 25(5B):749–757. doi:10.1016/0022-4731(86)90304-3 PubMedCrossRef

31.

Masamura S, Santner SJ, Heitjan DF, Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80(10):2918–2925. doi:10.1210/jc.80.10.2918 PubMedCrossRef

32.

Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R et al (1998) Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139(10):4164–4174. doi:10.1210/en.139.10.4164 PubMedCrossRef

Title: The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
Authors: Matthew J. Sikora
Kevin E. Cordero
Jose M. Larios
Michael D. Johnson
Marc E. Lippman
James M. Rae
Publication date: 01-05-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0080-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients

BRCA1 promoter methylation is associated with increased mortality among women with breast cancer

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Psychological impact of recall in high-risk breast MRI screening

Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families

Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer